News
QTTB
15.37
-0.26%
-0.04
Weekly Report: what happened at QTTB last week (0803-0807)?
Weekly Report · 3d ago
Oppenheimer Remains a Buy on Q32 Bio (QTTB)
TipRanks · 6d ago
Q32 Bio (QTTB) Gets a Buy from Wells Fargo
TipRanks · 08/06 11:18
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB)
TipRanks · 08/05 18:30
Q32 Bio tops estimates as alopecia drug advances toward late-stage trials
Seeking Alpha · 08/05 13:04
Q32 Bio Q2 EPS $(0.44) Beats $(0.54) Estimate
Benzinga · 08/05 11:21
Q32 Bio GAAP EPS of -$0.44 beats by $0.10
Seeking Alpha · 08/05 11:00
*Q32 Bio 2Q Research and Development Expenses $4.3M >QTTB
Dow Jones · 08/05 11:00
*Q32 Bio 2Q Loss/Shr 44c >QTTB
Dow Jones · 08/05 10:59
Press Release: Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 08/05 10:59
Q32 Bio: Q2 Earnings Snapshot
Barchart · 08/05 06:15
Weekly Report: what happened at QTTB last week (0727-0731)?
Weekly Report · 08/03 09:28
Twilio To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 07/28 12:19
Q32 Bio Price Target Raised to $36.00/Share From $13.00 by HC Wainwright & Co.
Dow Jones · 07/28 10:16
Q32 Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 07/28 10:16
HC Wainwright & Co. Maintains Buy on Q32 Bio, Raises Price Target to $36
Benzinga · 07/28 10:05
Q32 Bio price target raised to $36 from $13 at H.C. Wainwright
TipRanks · 07/28 10:00
Weekly Report: what happened at QTTB last week (0720-0724)?
Weekly Report · 07/27 09:29
Playing The Biotech Breakout With Insiders
Seeking Alpha · 07/23 19:15
Weekly Report: what happened at QTTB last week (0713-0717)?
Weekly Report · 07/20 09:28
More
Webull provides a variety of real-time QTTB stock news. You can receive the latest news about Q32 BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About QTTB
Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.